Literature DB >> 15660389

Sources of variability in histological scoring of chronic viral hepatitis.

Marie-Christine Rousselet1, Sophie Michalak, Florence Dupré, Anne Croué, Pierre Bedossa, Jean-Paul Saint-André, Paul Calès.   

Abstract

Inter-observer agreement on activity and fibrosis scores used in chronic viral hepatitis has only been studied under selected conditions. The aim of this study was to identify the sources of variability due to specimen characteristics and observers. This study included 254 liver specimens and 15 pathologists and used the Metavir score. In 44 specimens scored by 4 academic pathologists, agreement of Metavir score was good overall, but better for fibrosis (kappa = 0.59) than for activity (kappa = 0.43) and poor for lobular necrosis (kappa = 0.15). The mean agreement was better for senior (0.60 +/- 0.24) than junior pathologists (0.52 +/- 0.30, P < .05). Mean intrabserver agreement was better than inter-observer agreement (0.77 +/- 0.18 vs. 0.58 +/- 0.26, P < .01). In 157 specimens scored by 2 expert pathologists (one senior, one junior), agreement of Metavir score was only good but greatly improved after consensus reading (fibrosis: kappa = 0.48 and 0.77, activity: kappa = 0.44 and 0.70, respectively, before and after consensus). Several causes of disagreement were identified: specimen length, fibrosis class number, observer bias, and putative causes related to Metavir score or specimen. In an intercenter evaluation involving 59 specimens, 1 expert and 10 nonacademic pathologists, agreement was very poor and did not improve over 5 years for activity (kappa = 0.22-0.25) or fibrosis (kappa = 0.13-0.18). In conclusion, the level of experience (specialization, duration, and location of practice) has more influence on agreement than the characteristics of the specimen (length, fibrosis class number, miscellaneous factors). Agreement can be improved by experienced pathologist or consensus reading.

Entities:  

Mesh:

Year:  2005        PMID: 15660389     DOI: 10.1002/hep.20535

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  133 in total

1.  FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus.

Authors:  Keyur Patel; Mireen Friedrich-Rust; Yoav Lurie; Mircea Grigorescu; Carol Stanciu; Chuan-Mo Lee; Eugene R Schiff; Dieter Häussinger; Michael P Manns; Guido Gerken; Isabelle Colle; Michael Torbenson; Erik Pulkstenis; G Mani Subramanian; John G McHutchison; Stefan Zeuzem
Journal:  World J Gastroenterol       Date:  2011-11-07       Impact factor: 5.742

Review 2.  Histopathology of nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

3.  PET/CT with 18F Fluorocholine as an Imaging Biomarker for Chronic Liver Disease: A Preliminary Radiopathologic Correspondence Study in Patients with Liver Cancer.

Authors:  Sandi A Kwee; Linda Wong; Owen T M Chan; Sumodh Kalathil; Naoky Tsai
Journal:  Radiology       Date:  2018-01-09       Impact factor: 11.105

4.  Digital analysis of hepatic sections in mice accurately quantitates triglycerides and selected properties of lipid droplets.

Authors:  Fengxia Ge; Harrison Lobdell; Shengli Zhou; Chunguang Hu; Paul D Berk
Journal:  Exp Biol Med (Maywood)       Date:  2010-10-13

5.  Inter-observer variability in histopathological assessment of liver biopsies taken in a pediatric open label therapeutic program for chronic HBV infection treatment.

Authors:  Marek Woynarowski; Joanna Cielecka-Kuszyk; Andrzej Kałuzyński; Aleksandra Omulecka; Maria Sobaniec-Łotowska; Julian Stolarczyk; Wojciech Szczepański
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

6.  Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C.

Authors:  Keyur Patel; Katja S Remlinger; Terence G Walker; Peter Leitner; Joseph E Lucas; Stephen D Gardner; John G McHutchison; Will Irving; Indra Neil Guha
Journal:  Clin Gastroenterol Hepatol       Date:  2014-05-09       Impact factor: 11.382

7.  Enhanced liver fibrosis test using ELISA assay accurately discriminates advanced stage of liver fibrosis as determined by transient elastography fibroscan in treatment naïve chronic HCV patients.

Authors:  Dalia Omran; Ayman Yosry; Samar K Darweesh; Mohammed M Nabeel; Mohammed El-Beshlawey; Sameh Saif; Azza Fared; Mohamed Hassany; Rania A Zayed
Journal:  Clin Exp Med       Date:  2017-05-31       Impact factor: 3.984

8.  Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.

Authors:  Anna S Lok; James E Everhart; Raymond T Chung; Hae-Young Kim; Gregory T Everson; John C Hoefs; Joel K Greenson; Richard K Sterling; Karen L Lindsay; William M Lee; Adrian M Di Bisceglie; Herbert L Bonkovsky; Marc G Ghany; Chihiro Morishima
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

Review 9.  Magnetic Resonance Elastography of Liver: Current Update.

Authors:  Safa Hoodeshenas; Meng Yin; Sudhakar Kundapur Venkatesh
Journal:  Top Magn Reson Imaging       Date:  2018-10

10.  Reference Intervals of Fibrosis Index Based on Four Indicators in Healthy Elderly Chinese.

Authors:  Guo-Ming Zhang; Yong-Jie Xia
Journal:  J Clin Lab Anal       Date:  2016-03-08       Impact factor: 2.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.